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General Introduction 
Cells are surrounded by a lipid membrane, keeping the 
cell organelles together and acting as a border between 
the cell and its environment. The exchange of both 
material and information between the cell and the 
environment is strictly controlled. Many signalling 
molecules acting as primary messengers in the 
communication of cells are not able to pass the cell 
membrane, but are detected by receptor proteins 
spanning the membrane. The information of ligand 
binding to the extra-cellular part of the receptor is 
translated into the cell as an alteration of the intra-
cellular part. This change induces the action of intra-
cellular proteins. Some of these actions result in the 
generation of so-called second messengers. These 
molecules, of which cAMP is a classical example, 
spread the extra-cellular primary signal within the cell. 
cAMP – a second messenger 
cAMP, first identified in 1957 (1), is synthesised by 
adenylate cyclase (2) from ATP by the release of 
pyrophosphate and degraded to AMP by 
phosphodiesterases (for details see Box1). The 
interplay of adenylate cyclases and phosphodiesterases 
allows a strictly local and temporal control of the 
cAMP concentration within the cell. cAMP mediates 
such different effects as kinase activity, transcription 
activation, ion flux over membranes and activation of 
G-proteins. This implies the involvement of a number 
of different proteins. However most, if not all cAMP 
effects observed in normal eukaryotic tissues were 
attributed to protein kinase A (PKA). The kinase 
activity of PKA is dependent on cAMP. In fact, the 
activation of PKA by cAMP generated by adenylate 
cyclase after stimulation of the cell was one of the first 
second messenger systems discovered in the late 1950s 
and early 1960s. In addition cAMP was known to act 
on cyclic nucleotide dependent ion channels.  
In 1998 an additional target of cAMP was identified: 
Exchange protein directly activated by cAMP (Epac) 
(3;4). Epac is – like PKA – ubiquitously expressed in 
eucaryotes. Epac is an exchange factor specific for the 
small G-protein Rap. Rap is a molecular switch, that 
cycles between a GDP bound inactive and a GTP 
bound active state. In its active state Rap cause 
activation of signalling pathways in the cell. Epac 
induces in a cAMP dependent manner the transition 
from the GDP bound state to the GTP bound state by 
exchanging the nucleotides (Fig. 1B). Thus Epac 
regulates – like PKA – cellular signalling. It is of great 
interest to define the exact role of Epac in cAMP 
mediated signalling. 
Epac – a target of cAMP 
Epac consists of a regulatory and a catalytic part. The 
catalytic part contains a REM domain and a CDC25 
homology domain (Fig. 1A). The latter meditates 
guanine nucleotide exchange activity (GEF-activity) 
specifically on the small G-proteins Rap1 and Rap2. 
This activity is dependent on cAMP binding to the 
regulatory part. The individual domains of Epac are 
discussed below, for an overview see Fig. 1A. In higher 
organisms two isoforms of Epac, Epac1 and Epac2, 
exist. The major difference between Epac1 and Epac2 
is an additional N-terminal cAMP-binding domain in 
Epac2. In lower eukaryotes like Drosophila and C.
elegans,  only one form of Epac is identified, which is, 
due to the presence of an additional N-terminal cAMP-
binding domain, more related to Epac2. In these lower 
organisms however, this domain is less conserved and 
lacks some sequence features required for cAMP 
binding. A splice variant of Epac2 lacking the N-
terminal cAMP-binding domain as well as the DEP 
domain was identified in humans and mice (5). These 
findings, together with our observation that, in vitro,
the N-terminal domain is not required to maintain 
Epac2 in its inactive state in the absence of cAMP 
Fig. 1 A. Domain organisation of Epac1 
and Epac2. cAMP, cAMP-binding 
domain; DEP, Dishevelled Egl-10 
Pleckstrin; REM, Ras exchange motif; 
CDC25-HD, CDC25 homology domain. 
The splice variant of Epac2 (5) is 
indicated by a line. B. Epac in the 
context of signal transduction. cAMP 
leads to the activation of Epac, which 
catalyses the exchange of Rap-bound 
nucleotide. This process results in the 
formation of RapGTP. RapGTP in turn 
interacts with effector proteins, which 
cause a cellular response. A Rap-
independent role of Epac2 in exocytosis 
was suggested.
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Box1
Nine isoforms of adenylate cyclyase (also 
called adenylyl cyclase and adenyl cyclase) 
are described in humans by now(125;126). 
All mammalian adenylate cyclases are 
structurally homologous and consist of two 
6-trans-membrane-helix-domains and of two 
cytosolic domains, C1 and C2. The C1 
domains are highly homologous to the C2 
domains, so that the protein sequence 
contains two similar repeats. The C1 domain 
forms an intramolecular heterodimer with 
the C2 domain. The (correct) formation of 
the dimer is required for the catalytic 
activity, since the active site is at the C1/C2 
interface (127). 
Forskolin, originally isolated from Coleus 
Forskohlii, an traditional Indian medical 
plant, can directly stimulate Adenylate 
Cyclase. Crystal structure analysis of a 
heterodimer formed from recombinant C1 
and C2  domains had shown forskolin to be 
bound in the dimer interface but outside of 
the catalytic site. Thus forskolin seems to 
stabilise the dimer. Adenylate cyclase is 
mainly regulated by the Gα-subunits of 
heterotrimeric G-proteins. Gα-subunits with 
a stimulatory effect are called Gαs and those 
with an inhibitory effect Gαi. The regulatory 
effect is mediated in both cases by a direct 
interaction of the Gα subunit and the adenylate cyclase. Although structural data of a complex containing C1, 
C2, Gαs, forskolin and a non-hydrolysable ATP analogue are available it is not clear how the stimulatory 
effect is mediated (127). This is mainly due to the absence of any structural information of an inactive form of 
adenylate cyclase. Nevertheless, a conformational change after binding of Gαs was proposed. Whereas all 
isoforms of adenylate cyclase are stimulated by Gαs and almost all are inhibited by Gαi, additional regulation 
by Gβγ, calmodulin, PKC and PKA are described for some isoforms (125;126). 
(chapter 2), indicates that the N-terminal cAMP-
binding domain is most likely not involved in cAMP 
mediated regulation of Epac2. 
Exchange factors mediate their effects through their 
respective small G-proteins (Fig. 1B). However, a 
possible Rap-independent role of Epac2 in exocytosis 
was suggested (see below). Epac is a member of a 
group of Rap-specific exchange factors. These 
exchange factors are regulated by a wide variety of 
stimuli. The first identified exchange factor for Rap 
was C3G (6). After activation of receptor tyrosine 
kinases, C3G is recruited to the plasma membrane with 
the help of docking proteins such as Crk (7). This 
mechanism resembles the activation of Ras by the 
Grb2ƔSos complex (8). Three isoforms of GRP 
(CalDAG-GEF) are described, one of which is specific 
for Rap, one for Ras and the third for both Rap and Ras 
(9;10). The Ras specific GRP1 (CalDAG-GEF II) 
respond to the classical second messengers Ca2+ and 
Diacylglycerol (DAG). So far it has been not possible 
to demonstrate an allosteric regulation of these GEFs in
vitro and it was suggested that enrichment of DAG in 
membranes results in recruitment of CalDAG-GEF to 
these membranes (11;12). Little is known about the 
regulation of PDZ-GEF. PDZ-GEF contains a 
degenerated cAMP-binding domain (13), but evidences 
for a cAMP or cGMP mediated regulation of PDZ-GEF 
are published (14). However, we found by in vitro
experiments that the affinity of the potential cAMP-
binding domain to cAMP is very low and therefore a 
regulation by cAMP is most likely of no physiological 
relevance (15;16). An interaction between synaptic 
scaffolding molecule (S-Scam) and PDZ-GEF was 
reported, although the physiological relevance is not 
Generation of cAMP by adenylate cyclase. Adenylate cyclase
synthesises cAMP from ATP by the release of pyrophosphate.
Phosphordiesterase converts cAMP to AMP by cleaving the
phosphate. The interplay of adenylate cyclases and
phosphodiesterases controls the level of cAMP in the cell.
Adenylate cyclase itself is activated or inhibited by G-subunits of
heterotrimeric G-proteins.
General Introduction 
12
clear (17). Repac (Related to Epac), also called GFR 
(Guanine nucleotide exchange factor for Rap), (18) can 
be understood as Epac lacking the regulatory part. 
Repac is constitutively active and maybe regulated by 
interaction with other proteins. Along these lines an 
inhibition of Repac by M-Ras was shown (19). Thus 
cAMP dependent action on Rap by Epac takes place in 
the context of a complex regulation network. 
Epac2 – a mediator of exocytosis 
A pivotal role of cAMP controlled signalling in 
exocytosis is generally accepted. Whereas it was 
possible to attribute most effects to cAMP-induced 
PKA activation, others are described as PKA-
independent. Recently it was shown that Epac2 
activation is directly involved in the release of insulin 
from pancreatic β-cells (20-22). How this contribution 
of Epac2 is mediated is not known in detail, but it was 
demonstrated that Epac2 increases the intracellular 
Ca2+ concentration ((Ca2+)i), most likely by the release 
of Ca2+ from the endoplasmatic reticulum via 
ryanodine sensitive Ca2+ channels (21;22). 
Intriguingly, there is evidence that Epac2 acts at least 
in part independently of Rap. It was shown by two-
hybrid-analysis as well as by pull-down assays that 
Epac2 interacts directly with Rim2, known as an 
effector of the small G-protein Rab3, which is itself 
involved in exocytosis. This interaction is mediated by 
the PDZ-domain of Rim2 (20) (Fig. 2). That this 
interaction between Epac2 and Rim2 is responsible for 
the effect of Epac2 in exocytosis is formally not shown, 
but implicated. Transfection of the single PDZ-domain 
of Rim2 blocks the Epac2 mediated effect in 
exocytosis. This blockage can be overcome at least 
partially by co-expression of Epac2 (23). A general 
function of Rim2 in exocytosis is well established. 
Since Rim2 is localised in the active zone of the 
targeted membrane, where vesicle fusion occurs, and 
since Rab is localised in the vesicle membrane, it was 
suggested that the interaction between Rim2 and Rab 
anchors the vesicle at the active zone in a ready-to-
fuse-state (24). This distribution of Rim2 and Rab was 
also shown for pancreatic β-cells (25). Rim also 
interacts directly with SNAP25 and Synaptogamcin, 
which are both part of the SNARE complex (Fig 2). 
The SNARE complex is involved in anchoring the 
vesicles at the active zone and it undergoes subsequent 
rearrangements, required for the fusion process itself. 
At least two events contibute to these rearrangements: 
(a) a conformational change of syntaxin, a component 
of the SNARE complex. This conformational change 
was confirmed by NMR studies (26). It was shown 
genetically that Rim is upstream of unc13 and that 
unc13 is upstream of the conformational change of 
syntaxin (27). (b) an increase in (Ca2+)i. Some protein-
protein interactions in the SNARE complex are Ca2+-
dependent (28). The general requirement of an increase 
in (Ca2+)i was demonstrated for a multitude of model 
systems for exocytosis (29-35). 
As mentioned above it was shown that Epac2 
activation results in an increase of (Ca2+)i (21;22). 
There are different possibilities how Epac2 could cause 
this increase: (a) RIM is known to interact with N- and 
L-type Ca2+-channels (28). (b) Epac was shown to 
interact with the SUR1 subunit of KATP-channels. 
These channels are involved in the regulation of 
depolarisation events, which lead to insulin secretion 
via a (Ca2+)i increase (36). (c) Rap was shown to 
Fig. 2 Epac2 is involved in exocytosis. The different possibilities by which Epac2 could influence exocytosis are
shown. Arrows with two arrowheads indicate interaction whereas arrows with only one arrowhead indicate
activation. The individual pathways are discussed in the text. Ca2+ stands for Ca2+ binding domain. 
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interact with a Ca2+-ATPase (37;38). The physiological 
relevance of all these interactions is unknown. 
It is important to note, that the effect of Epac2 in 
exocytosis is cAMP dependent. So far it has not been 
shown that the interaction between Rim and Epac2 is 
cAMP dependent. Neither a cAMP dependent 
localisation of Epac2 is demonstrated. One possible 
explanation for these findings is that the Epac-Rim-
pathway is necessary but not sufficient for exocytosis 
and that additional signals by RapGTP are required 
(Fig. 2). 
Rap – a target of Epac 
The small G-protein Rap cycles between a GDP bound 
inactive state and a GTP bound active state, and 
therefore acts as a molecular switch. The transition 
from the GDP to the GTP bound state is mediated by 
Guanine Nucleotide Exchange Factors, like Epac, 
which accelerate the intrinsically slow dissociation rate 
and cause thereby the loading with GTP (Fig. 1B, for 
details see Box 2). The transition of Rap back to the 
inactive state is achieved by the GTPase activity of Rap 
resulting in the hydrolysis of GTP to GDP. This 
activity is stimulated by GTPase activating proteins 
(GAP). GDP stays bound to the protein, whereas the 
phosphate is released immediately. Only in its GTP 
bound state Rap is able to interact with so-called 
effector proteins. Activation of the effector after 
binding to the G-protein is either due to a 
conformational change of the effector or to its 
relocalisaton. The term “activation of a G-protein” is 
often understood from the point of view of signalling, it 
refers therefore to the transition of the G-protein from 
the “inactive” GDP to the “active” GTP bound state. It 
does, however, not refer to the activation of the 
enzymatic activity of the G-protein, i.e. the hydrolysis 
of GTP. 
Rap was originally identified in a screen for cDNAs 
able to revert the transforming phenotype of oncogenic 
K-Ras (39). For this reason it was called Krev (K-Ras 
reverting phenotype). From this initial observation, Rap 
was proposed to be an antagonist of Ras mediated 
effects. This model was supported by the finding that 
Rap is able to bind to most of the effectors of Ras (40-
43). Thus it was proposed that RapGTP traps Ras 
effectors in an inactive complex. However, it was 
shown that Rap is able to induce cell transformation as 
well (44), and in the meantime it seems to be clear that 
Rap mediated signalling is independent of Ras. Most 
importantly a pivotal role of Rap in integrin signalling 
was shown (see below), (for review see (45)). 
Rap in integrin signalling 
Integrins are mediators of cell-cell-adhesion as well as 
of cell-matrix-adhesion and thus regulate such 
important processes as the correct cohesion of tissues, 
the interaction of immune cells with their targets, or the 
mobility of cells during development. Integrins are 
heterodimers consisting of a longer α- and a shorter β-
chain. Both chains are transmembrane proteins that 
consist of a relatively short C-terminal cytosolic tail 
and of several extracellular N-terminal domains. The 
extracelluar domain interacts with cell surface proteins 
of other cells in the case of cell-cell-adhesion or with 
proteins of the extracellular matrix in case of cell-
matrix-adhesion. The interaction partners are called 
ligands of integrins. The adhesion in physical sense is 
mediated by these interactions. 
Adhesion of cells and thus integrin function is tightly 
regulated. The regulation occurs at different levels. The 
adhesion capability of integrins is determined by the 
“affinity” and the “avidity” state of the integrins. Both 
states are targeted by regulation processes. “Affinity” is 
defined as the affinity of a protein-ligand interaction in 
the thermodynamic sense. “Avidity” is less clear in 
definition. The term summarises phenomena of integrin 
density, often understood as local densities, clustering 
and accessibility. These properties are in part 
controlled by the attachment of integrins to the 
cytoskeleton. Induction of a highly adhesive state 
requires detachment, movement and reattachment of 
integrins. A signalling process is called inside-out 
signalling if a signal resulting in an alteration of the 
integrin state is generated in the cell (upon stimulation 
of the cell). On the other hand, integrins cause 
signalling events in the cell depending on their ligand-
state, is called outside-in signalling. Thus adhesion by 
itself influences cellular events. The inhibition of 
proliferation by cell-cell contacts (contact inhibition) is 
well known example. The initial ligand binding leads 
to an amplification of adhesion. 
Two possible experimental ways of inducing integrin 
activity and therefore adhesion have to be 
distinguished. (a) application of suitable factors leading 
to activation of receptors that control signalling which 
induces integrin activity (b) direct targeting of the 
integrins by application of Mn2+ or activating 
antibodies. The later activation mechanism is based on 
the notion that the interaction of integrins with their 
ligands is absolutely depending on divalent cations 
such as Mg2+ and Ca2+. Each integrin chain contains 
four or five extracellular ion binding sites. Ion binding 
induces a high affinity binding  state of the integrin. 
Similarly, some antibodies are able to induce this state. 
The requirement for Rap in cell-adhesion induced by 
CD31 (46), CD14 (47), the β-adrenergic receptor (48), 
erythropoietin (49), interleukin-3 (49), CD98 (50), 
phorbol ester (51), the thrombin receptor (52) or G-
CSF (53) was either shown directly or is strongly 
implicated. Although the importance of Rap is 
unambiguous, it is not clear how Rap mediates these 
effects. Establishment of the final adhesion state after 
initial receptor stimulation requires a set of signalling 
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events, each of which may be influenced by Rap. 
Signals caused by the receptor have to influence the 
affinity or avidity state of the integrin and may 
additionally control integrin-independent requirements 
for adhesion. It is likely that Rap is involved in these 
processes. The β2-adrenergic receptor stimulates the 
activation of adenylate cyclase and thereby the 
generation of cAMP, which can activate Epac. An 
Epac-selective cAMP analogue is indeed able to induce 
adhesion (48). C3G and the adaptor protein CrkL are 
required for adhesion in many cellular systems (54-59). 
The C3G•CrkL complex becomes membrane-localised 
through interaction of SH2 domain of CrkL after 
activation of receptor tyrosine kinases. Thus, the 
formation of RapGTP is directly linked to receptor 
stimulation. The activation state of integrins can be 
monitored by monoclonal antibodies that recognise 
only the active state of the integrin. In this way it was 
shown, that Rap is required for receptor induced 
integrin activation (46). 
Mn2+ and antibody induced cell adhesion requires Rap 
as well (46;60). Experiments with purified integrins 
have shown that Mn2+ (61) and activating antibodies 
(62;63) induce a high affinity state of the integrin 
without the requirement of any additional factors in
vitro. On the other hand cells expressing integrins 
lacking the cytosolic tail are not able to establish a 
stable adhesion state. Thus Rap is requires for the 
ability of integrins to function as adhesion molecules in
vivo, perhaps by regulating the connection of integrins 
to the cytoskelett. 
Domain structure of Epac 
The DEP domain – correct localisation of Epac may 
play a role in cell division 
A certain sequence in Dishevelled was found to be 
conserved in other proteins as well and was therefore 
nominated a new domain (64). This domain was called 
DEP domain for Dishevelled, Egal-10 and Pleckstrin,
the most prominent proteins identified in this search. 
Interestingly, also Epac (referred to as ymx5) was 
identified and recognised as a protein containing a DEP 
domain, a cAMP-binding domain and a CDC25-
homology domain, but not further noticed (64). Since 
many of the found proteins were known to be 
membrane localised or otherwise connected to 
membrane functions, the DEP domain was suggested to 
be involved in membrane localisation. This prediction 
was later confirmed for the DEP domain of 
Dishevelled. It is not clear whether the DEP domain 
mediates localisation by a protein-protein interaction or 
by a direct membrane interaction, since interaction 
partners are hitherto unknown. Evidence for both 
scenarios is described in literature. Wang et al. (65), 
who solved the NMR structure of the DEP domain 
from Dishevelled, identified a positively charged 
surface area that may be involved in a direct but 
unspecific membrane interaction. On the other hand, it 
is possible to use the single DEP domain of 
Dishevelled as a dominant negative suppresser of 
Dishevelled mediated activation of the wnt signalling 
pathway (65). Introduction of point mutations in the 
DEP domain in the context of a full length Dishevelled 
represses wnt signalling (65). Both findings argue for 
protein-protein interactions. 
The cellular localisation of Epac at the plasma 
membrane was shown to be dependent on the DEP 
domain (66). In addition, localisation of Epac1 at 
perinuclear membranes and a co-localisation with 
mitochondria was observed (66). The mitochondrial 
localisation is due to an N-terminal mitochondrial 
targeting sequence. 
The localisation of Epac1 is dependent on the cell 
cycle. Whereas Epac1 is localised at the plasma 
membrane in quiescent cells, it is found to be co-
localised with the mitotic spindle and the centrosomes 
during metaphase and around the chromosomes during 
anaphase (66). Whether Epac plays a role cell cycle 
progression is at the moment just a fascinating object 
of speculation. 
In addition, during anaphase and telophase Epac is 
enriched in the area where the two daughter cells are 
separated from each other (66). Intriguingly it was 
shown that the correct formation of adherens junctions 
is effected in Rap-negative Drosophila cells (67). It 
was suggested that Rap is responsible for the correct 
deconstruction of the adherens junctions and the 
contractile ring after cell division (67). A putative link 
between Rap and adherens junctions is the nucleotide-
dependent interaction of Rap with AF-6 (68;69), which 
was shown to be localised at adherens junctions (70;71) 
as well as at tight junctions (72;73). AF-6 in turn 
interacts with ZO-1 (74;75), which is associated with 
the adherens junction complex protein α-catenin (76). 
These findings together imply an attractive model: 
Epac activates Rap in the interface of the dividing cell, 
where separation of the daughter cells occurs. This 
separation process is then completed by the action of 
Rap.
The CDC25-homology domain – structural basis of 
nucleotide exchange 
Each family of the Ras superfamily has its own type of 
exchange factors, which are structurally not related to 
each other. This is evident from the crystal structures 
determined so far (Fig. 3). The structures of three 
exchange factors have been determined alone and in 
complex with the corresponding G-proteins: the 
DH/PH domain of Sos alone (77) and in complex with 
CDC42 (78), RCC1 (79) alone and in complex with 
Ran (80), the sec domain of ARNO (81) alone and in 
complex with Arf (82). The structures of three 
exchange factors have been determined only in 
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complex with their corresponding G-protein: the 
REM/CDC25 homology domain of Sos in complex 
with Ras (83) the DH/PH domain of Tiam in complex 
with Rac (84) and SopE in complex with CDC42 (85). 
SopE is a bacterial toxin and its structure does not 
correspond to the canonical DH/PH motif of the 
mammalian exchange factors for the Rho family. In 
addition the structure of Mess4 (86), an exchange 
factor for Rab (87), has been determined in the absence 
Rab.
The exchange activity of Epac is mediated by its 
CDC25-homology domain. This domain is found in all 
exchange factors for members of the Ras family, 
although each exchange factor is characterised by a 
profile of specificity towards the individual members 
of the Ras family. However, the general architecture of 
all CDC25 homology domains is identical, and the 
Ras•SOS complex is thus a model for the whole 
family. CDC25-homology domains are always found 
together with a REM domain, although the relative 
Fig. 3 Guanine nucleotide exchange factors are structurally not conserved. Representative structures for the different
families of exchange factors are shown if data is available in complex with their small G-proteins. The G-protein is
coloured in light grey, the catalytic domain in black and additional domains of the exchange factor are in dark grey. These
additional domains for example the REM domain of Sos are not required for the catalysis itself. The figure was generated
by the use of the programs molscript (128) and raster3d (129). 
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Box2
The sequence of the exchange reaction is summarised in the figure. The nucleotide affinity of the G-
protein is very high, and the intrinsic dissociation rate of the nucleotide is very slow. Binding of the 
exchange factor to the nucleotide-bound G-protein leads to an intermediate trimeric complex. The trimeric 
complex decays either by the release of the exchange factor or of the nucleotide. The latter results in the 
nucleotide free G-protein bound to the exchange factor. This complex is stable, can be purified in the 
absence of nucleotide and can be used for structural studies. The trimeric complex can be regenerated by 
binding of a nucleotide and, in case it decays by the release of the exchange factor, the nucleotide which 
had been originally bound to the G-protein is exchanged for the nucleotide that had rebound to the 
complex of G-protein and exchange factor. Thus, the exchange factor does not exchange one type of 
nucleotide for another one, e.g. GDP for GTP, due to a selection or discrimination process. It just 
catalyses the release of any nucleotide bound to the G-protein. Due to its GTP hydrolysing activity the G-
protein in the cell is predominately bound to GDP. However, the GTP concentration in the cell is one ore 
two orders of magnitude higher than the GDP concentration. Thus, most often GTP rebinds just by chance 
to the complex of nucleotide free G-protein and exchange factor. This mechanism requires that there is no 
competition between the nucleotide and the exchange factor for the G-protein. Competition in the 
classical sense means that the G-protein can bind to the nucleotide and the GEF, but the binding of the 
nucleotide excludes the binding of the GEF 
and the binding of the GEF excludes the 
binding of the nucleotide. Competition results 
therefore in displacement of one binding 
partner but not in the exchange of one binding 
partner. It is thus necessary that the nucleotide 
and the GEF can bind at the same time. On the 
other hand, a totally independent binding 
would result in a stable trimeric complex and 
again there would be no exchange. Thus a 
combination of “binding at the same time” and 
displacement is required. The known 
structures of G-proteins in complex with 
exchange factors demonstrate how this 
requirements are realised. 
The following discussion will focus on the 
Ras•Sos complex. The binding of the 
nucleotide can be split into two major 
determinants, the contribution of the base and 
of the phosphate-sugar moiety. An Mg2+ ion is 
pivotal for binding of the nucleotide, by co-
ordinating the negatively charged phosphates 
as well as residues of the G-protein. These 
moieties of the nucleotide bind to quite 
separated areas of the binding pocket. Binding 
of Sos interferes predominantly with the 
binding of the phosphate-sugar moiety. The 
so-called P-loop and the switch I region are 
bent by Sos in a way that opens up the binding 
pocket. This abolishes the binding of the 
phosphates and displaces the Mg2+. The 
binding area for the base is more or less 
unperturbed (see figure). Thus the binding of 
the nucleotide is weakened sufficiently to 
allow a high dissociation rate of the 
nucleotide, but rebinding is possible: base 
first, displacement of Sos second. 
A. Catalysis on nucleotide exchange by GEFs. The
reaction scheme of the interaction between a GEF and a
small G-protein (here Rap) is shown. For a detailed
explanation see text. B. Action of Sos on Ras. The GppNHp
bound Ras (light grey) (130), was superimposed to the
nucleotide free Ras of the Ras•Sos complex (91). Only the
elements of the nucleotide free Ras that are different from the
nucleotide bound Ras are shown (black). The helix from Sos
which bends switch I away to open the nucleotide binding
pocket is shown in dark grey.
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location of both domains within the protein sequence is 
highly variable (88). The REM domain is not required 
for the catalytic activity, since the single CDC25 
homology domain is sufficient to stimulate nucleotide 
exchange in vitro  (89;90). No direct interaction 
between the REM domain and Ras was observed in the 
structure of the Ras•SOS complex, and it was 
suggested that the REM domain stabilises the CDC25 
homology domain by shielding hydrophobic residues 
against the solvent (91). More recently an activity 
modulating role of the REM domain has been 
suggested. Margarit et al. crystallised a 
Ras•Sos•Ras•GTP complex, in which an additional 
GTP-loaded Ras interacts with the REM domain and 
the CDC25 homology domain independently of the 
active site of Sos. They also demonstrated that the 
presence of Ras•GTP can accelerate the rate of 
nucleotide exchange (92). However, the structural data 
can not fully explain the observed biochemical effects. 
Although the structure of different exchange factor 
families is evolutionary not conserved, the basic 
principle of the catalytic mechanism is the same. It was 
analysed in great detail for the Ran-RCC1 (93) and for 
the Ras-CDC25 system (90), the detailed mechanism of 
exchange is described in Box 2. 
The cAMP-binding domain – and the experimental 
problem of targeting signalling pathways 
specifically
Such different functions as kinase activity, 
transcription activation, ion fluxes and activation of 
small G-proteins are all directly controlled by the 
cyclic nucleotides cAMP and cGMP. This implies the 
involvement of quite a number of different proteins. 
However, a common feature of all these proteins is a 
cyclic nucleotide binding domain (Fig. 4). These 
domains are homologous in sequence and share 
consensus motifs indicative of cyclic nucleotide 
binding (for review see (94)). The three-dimensional 
architecture of the domains is identical, as it is evident 
from the structures solved so far ((95-97), chapter 4). 
The classes of cAMP or cGMP regulated proteins, as 
shown in figure 3, will be described in the following 
section. (Epac is excluded from this short overview, 
since it is subject of this thesis.) 
PKA:
The cAMP-dependent serine/threonine protein kinase 
A (PKA) was one of the first kinases identified and 
became a paradigm of second messenger systems. 
PKA is a heterotetramer, consisting of 2 regulatory 
and 2 catalytic chains (Fig. 4). Four different 
regulatory chains (RIα, RIβ, RIIα and RIIβ) and three 
different catalytic chains (Cα, Cβ and Cγ) are known. 
Each regulatory chain contains two cAMP-binding 
sites, a pseudosubstrate sequence blocking the kinase 
active site and a dimerisation sequence. Binding of 
cAMP results in the release of the catalytic chains from 
the complex. The free catalytic domain is active and 
phosphorylates a multitude of protein targets. An 
additional mode of regulation is realised by the protein 
kinase-A inhibitor protein (PKI) which contains a 
pseudosubstrate sequence and is able of binding and 
thus inhibiting the free catalytic domain. The 
regulatory subunits bind to A-kinase anchoring protein 
(AKAP) which is associated with the cytoskeleton and 
is thereby involved in the control of PKA localisation. 
(For review see (98)) 
PKA controls a lot of physiological processes, the most 
important ones of which are listened in the following: 
Glycogen storage (an example for the involvement of 
PKA in metabolism): Activation of PKA results in 
decomposition of glycogen to glucose-1-phosphate, 
which is supplied to glycolysis or released as glucose 
from liver cells into the blood. This effect is propagated 
on three levels. First, glycogen-synthetase is 
phosphorylated and thus inactivated by PKA. Thus the 
(re)synthesis of glycogen is inhibited. Second, 
Phosphorylase-kinase is phosphorylated and thereby 
activated by PKA. Activated Phosphorylase kinase in 
Fig. 4 Domain architecture of proteins containing cAMP-
binding domains. PKA (protein kinase A) forms an inactive
heterotetramer in the absence of cAMP, which consists of 2
regulatory and 2 catalytic subunits. Each regulatory chain
contains two cAMP-binding and one dimerisation domain.
The catalytic subunits containing a kinase domain are
released from the inactive heterotetramer after cAMP
binding. In PKG (protein kinase G) two cGMP-binding
domains and one kinase domain are localised in one
polypeptide chain. An additional cGMP binding domain is
found in PKG from protozoa. CAP (catabolite gene activator
protein) forms a homodimer, which interacts with DNA after
cAMP binding and induces transcription, (DNA, DNA-
binding domain). Cyclic nucleotide dependent ion channels
are built from six transmembrane helices. The cyclic
nucleotide binding domain is localised at the C-terminus. 
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turn phosphorylates and thus activates glycogen-
phosphorylase, which cleaves glycogen to glucose-1-
phosphate. Third, PKA phosphorylates 
phosphoprotein-phosphatase-inhibitor, which in its 
phosphorylated state inhibits phosphoprotein-
phosphatase. Dephosphorylation and thus inhibition of 
glycogen-phosphorylase is thus prevented. (For review 
see (99;100)) 
Muscle relaxation: The hormonal control of muscle 
contraction is mainly mediated by cAMP. Myosin light 
chain kinase is activated by binding to the Ca2+-
Calmodulin complex, but inhibited by phosphorylation 
by PKA. Phosphorylation of myosin is required for 
muscle contraction. Activation of PKA results therefore 
in muscle relaxation. 
Gene transcription: The cAMP response element 
(CRE) was identified as a consensus sequence in 
promoter regions of genes which are expressed in 
response to cAMP stimulation. Transcription factors of 
the cAMP response element binding protein family 
(CREB-family) are homodimers, which initiate gene 
transcription after phosphorylation by PKA. The free 
catalytic domain of PKA can directly enter the nucleus 
once released from the inactive complex.  
Further direct effects in signal transduction: Many 
targets of PKA are elements of a wide variety of 
signalling pathways, which can be initiated, modulated 
or inhibited by phosphorylation. The review of the 
huge number of reports dealing with this subject is 
outside the scope of this thesis, which focuses more on 
the mechanistic aspects of the regulation of Epac. 
Isolated examples are discussed where required. 
PKG:
In contrast to PKA, two cGMP binding sites and a 
kinase domain are combined within one polypeptide 
chain (Fig. 4), which forms homodimers mediated by a 
N-terminal leucine zipper. Binding of cGMP induces 
kinase activity, most likely due to a conformational 
change in the regulatory region which releases an 
intramolecular interaction between the regulatory and 
the catalytic part. Thus PKG imitates the regulation 
mechanism of PKA. The cyclic nucleotide binding 
domains of PKA and PKG are highly related. Three 
isoforms of PKG (PKGIα, PKGIβ and PKGII) exist. 
PKGIα and PKGIβ are splice variants, which differ 
only in the extreme N-terminus. PKGI is found in the 
cytosol and therefore termed soluble, whereas PKGII is 
membrane associated (for review see (101)). An 
important function of PKGII is the phosphorylation and 
thereby stimulation of the ion channel cystic fibrosis 
transmembrane conductance regulator (CFTR) ((102), 
for review see (103)). In addition PKG plays an 
important role in the cardiovascular system (for review 
see (104)). For a general review of cellular function of 
PKG see (101;105;106). 
Recently a novel class of PKG was discovered in 
protozoa (107). These kinases contain a third cGMP 
binding domain “inserted” between the two N-terminal 
cGMP-binding domains and the C-terminal kinase 
domain (Fig. 4). Biochemical analysis have shown a 
functional relevance of all three domains (108;109). 
CAP:
The catabolite gene activator protein (CAP) is found 
only in bacteria. It is a homodimer and binds to DNA 
only in the presence of cAMP (Fig. 4). CAP can initiate 
gene transcription by a direct interaction with RNA-
polymerase. Best known is the function of CAP in 
initiating gene expression in the lac operon system. 
Cyclic nucleotide regulated ion channels:
Some cation channels are directly regulated by a 
cytosolic cyclic nucleotide binding domain. Binding of 
cyclic nucleotide either modulates or controls the ion 
flux depending on the channel type. cAMP gated ion 
channels play a specialised role in the olfactory system 
and cGMP gated ion channels control the ion flux of 
the rods and cones in the visual system (for review see 
(110))
As can be seen from this summary, very different 
cAMP (and cGMP) binding proteins are known. 
However, most of these proteins are well separated 
from each other, either by tissue specific expression or 
by restriction to a relative small appanage of the 
kingdoms of life. Cyclic nucleotide gated ion channels 
are, apart from their specialised function as pacemaker 
channels in the heart, assumed to be restricted mainly 
to the visual and olfactory sensory systems. The 
catabolite gene activator protein is found in bacteria 
only but not in any higher organism. 
The situation became more complex with the discovery 
of Epac. Both Epac and PKA are widely expressed. As 
discussed above Epac acts on the small G-protein Rap, 
a classic field of signal transduction. PKA regulates 
gene transcription and acts on many elements of 
signalling systems (The function of PKA in 
metabolism is not too important in this context). One 
has to assume that PKA and Epac mediated signalling 
interfere with each other. This dilemma is illustrated 
impressively by Rap itself. A cAMP dependent control 
of Rap and Rap-mediated effects was already noticed 
before the discovery of Epac (44;111). Rap1GAP was 
shown to be phosphorylated by PKA (besides CDC2), 
although without any influence on the in vitro activity 
(112;113). Rap is phosphorylated by PKA (114), 
although studies with a Rap mutant lacking the 
phosphorylation site in Drosophila show no 
abnormalities (115). These findings argued for a role of 
PKA in the regulation of Rap. However the much more 
direct link turned out to be Epac (3;4). In consequence, 
experiments have to be designed in a way that 
distinguishes between PKA and Epac mediated effects. 
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This could be achieved by the specific activation or 
inhibition of these pathways. 
Two major ways to stimulate cAMP dependent 
pathways are in use practical. One is to activate 
adenylate cyclase and the other is to apply external 
cAMP or cAMP analogues. Stimulation of adenylate 
cyclase by Forskolin resembles the natural cellular 
generation of cAMP (Box 1), but clearly does not 
discriminate between PKA and Epac. The low 
permeability of the cell membrane for cAMP makes the 
simple addition of cAMP to cell cultures dishes 
ineffective. Various derivatives of cAMP, with an 
increased membrane permeability are available and 
widely used. The binding of these cAMP analogues to 
PKA is well characterised (116;117), and the binding 
to Epac is analysed in chapter 5 of this thesis. Only two 
cAMP based inhibitors of PKA are known, Rp-cAMPS 
and Sp-cAMPN(CH3)2, which compete with cAMP for 
the binding to the regulatory subunit (118;119) (for 
details see chapter 4 and 5). The usability of these 
analogues is limited due to their reduced affinity for 
PKA in comparison to cAMP (118;119). A common 
target for PKA inhibitors is the kinase domain itself. 
The kinase activity can be inhibited by substrates like 
peptides, which do bind to the active site but do not 
accept a phosphate group (120;121). The probably 
most widely used inhibitor for PKA is H89, which 
competes with ATP for binding to the kinase domain 
((122), for review see (123)). 
Thus, experiments have to distinguish carefully 
between PKA and Epac mediated effects. This is 
possible by the use of PKA specific inhibitors as well 
as the resently describe Epac specific activtor 8-pCPT-
2’-O-Me-cAMP ((22;124) chapter 5). 
Scope of this thesis 
The more recently discovered Epac and the long known 
PKA are both major players in the intracellular cAMP 
mediated signalling. The activity of both proteins is 
controlled by a cAMP domain of very similar 
architecture. The effect of cAMP caused in the cell is 
therefore a result of both Epac and PKA activity. 
The aim of this thesis was to elucidate the mechanism 
by which cAMP activates Epac. 
We describe a biochemical characterisation of Epac in 
chapter 2 and 3. The inactive state of Epac is 
maintained by an intramolecular interaction between 
the cAMP-binding domain and the catalytic region and 
terminated by the release of this interaction upon 
cAMP binding. We identified a short conserved motif 
in Epac that is responsible for this interaction. 
Structural information was only available of the 
cAMP-binding domains of PKA and CAP in complex 
with cAMP. We determined therefore in chapter 4 the 
crystal structure of the regulatory region of Epac2 
containing two cAMP-binding domains and one DEP 
domain in the cAMP free state. In fact, this is the first 
of a cAMP-binding domain in the absence of ligand. 
From this data we deduce a model of a cAMP induce 
conformational change that is transferred throughout 
the cAMP-binding domain to the catalytic domain. 
This mechanism seems to be universal for all cyclic 
nucleotide binding proteins. 
Finally we analysed in chapter 5 the molecular basis for 
the action of Epac specific cAMP analogues which 
allows to discriminate between Epac and PKA 
mediated effects in vivo.
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Summary 
Epac is a cAMP dependent exchange factor for the small GTP-
binding protein Rap. The activity of Epac is inhibited by a direct 
interaction between the C-terminal helical part of the cAMP-
binding domain, called the LID, and the catalytic region, which is 
released after binding of cAMP. Here we show that the activation 
properties are very sensitive to modifications of the cyclic 
nucleotide. Some analogues are inhibitory whereas others are 
stimulatory, some are characterised by a much higher activation 
potential than normal cAMP. Mutational analysis of Epac allows 
insights into a network of interactions between the cyclic 
nucleotides and Epac. Mutations in the LID region are able to 
amplify or to attenuate selectively the activation potency of cAMP 
analogues. The properties of cAMP analogues previously used for 
the activation of the cAMP responsive protein kinase A (PKA) and 
of 8-pCPT-2’-O-Me-cAMP, an analogue highly selective for 
activation of Epac were investigated in detail. 
Introduction
Epac1 (exchange protein directly activated by cAMP) is a cAMP-
responsive guanine nucleotide exchange factor (GEF) for the small 
GTP-binding proteins Rap1 and Rap2 (1;2). Two isoforms of Epac, 
Epac1 and Epac2, were described in mammalian cells, both 
containing a regulatory and a catalytic region (Fig. 1). The catalytic 
region contains a CDC25 homology domain and a Ras exchange 
motif (REM) domain. Whereas the CDC25-homology domain 
alone is sufficient to mediate the catalytic activity (3;4), the REM 
domain of SOS has been shown to stabilise the CDC25-homology 
domain structurally without being directly involved in the 
interaction with Ras (5). More recently an activity-modulating 
function of the REM domain was suggested (6).  
The regulatory domain of Epac contains a cAMP-binding domain 
and a DEP domain. The DEP domain mediates membrane 
localisation of Epac and is not involved in regulation of the 
exchange activity in vitro. The cAMP binding domain inhibits the 
catalytic activity in the absence of cAMP. The inhibition is released 
after binding of cAMP. An additional N-terminal cAMP binding 
domain is present in Epac2. This domain is not required to maintain 
the inactive state of Epac2 in the absence of cAMP (7). 
Insight in the structural basis of the regulatory mechanism was 
obtained from the x-ray structure of the regulatory region of Epac2 
containing both cAMP binding domains and the DEP domain. The 
structure was solved in the absence of cAMP and was the first 
structure of a cAMP binding domain in the ligand-free state (8). 
Based on a structural comparison with cAMP bound regulatory 
subunits of PKA (9;10) it was proposed that cAMP binding induces 
a conformational change in the phosphate binding cassette (PBC) 
(8). This conformational change allows a C-terminal helix 
containing a HINGE region and a LID region to bend towards the 
cAMP binding site and to cover cAMP2 (8). Considering the high 
conservation of residues involved in the conformational change, the 
proposed model seems to account for the activation not only of 
Epac, but also of PKAs and cAMP-regulated ion channels.  
When analysing the role of the LID region of Epac in more detail, 
we observed that a conserved VLVLE sequence in the C-terminal 
end of the LID region is mediating the inhibition of the catalytic 
region. Indeed, mutation of this region resulted in a constitutively 
active Epac. Surprisingly, single point mutations in the LID region 
either abolished cAMP induced activity almost completely or 
resulted in an activity even higher then that of the wt protein. This 
indicated that after binding of cAMP the LID region regulates the 
activation status of Epac.2
1 The abbreviations used are: Epac, exchange protein directly activated vy cAMP; GEF, guanine nucleotide exchange factor; REM, Ras
exchange motif; DEP, Dishevelled, Egal-10, Pleckstrin; PKA, protein kinase A; 8-Br-cAMP, 8- Bromoadenosine-3', 5'-
cyclicmonophosphate; 2-Cl-cAMP, 2- Chloroadenosine- 3',5'-cyclicmonophosphate; 8-Cl-cAMP, 8- Chloroadenosine-3',5'-
cyclicmonophosphate; 2’ dcAMP, 2'-Deoxyadenosine-3',5'-cyclicmonophosphate; cIMP, Inosine-3',5'-cyclicmonophosphate; 8-MA-cAMP,
8- Methylaminoadenosine-3', 5'-cyclicmonophosphate; N6-phenyl-cAMP, N6-Phenyladenosine-3',5'-cyclicmonophosphate; 2’-O-Me-cAMP,
2'-O-Methyladenosine-3',5'-cyclicmonophosphate; 8-pCPT-cAMP, 8-(4-Chlorophenylthio)adenosine-3',5'-cyclicmonophosphate; 8-pCPT-
2’-O-Me-cAMP, 8-(4- Chlorophenylthio)-2'-O-methyladenosine-3',5'-cyclicmonophosphate; 8-PIP-cAMP, 8- Piperidinoadenosine-3',5'-
cyclicmonophosphate; Rp-cAMPS, Adenosine-3',5'-cyclicmonophosphorothioate, Rp-isomer; Sp-cAMPS, Adenosine-3',5'-
cyclicmonophosphorothioate, Sp-isomer; cXMP, Xanthosine-3', 5'-cyclicmonophosphate 
2 Rehmann et al. JBC in press 
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Recently, we identified a novel cAMP analogue, 8-pCPT-2'-O-Me-
cAMP, which binds and activates Epac efficiently both in vitro and 
in vivo. Most importantly, this compound was completely 
insensitive in activating PKA both in vitro and in vivo (11). Here 
we have characterised 8-pCPT-2'-O-Me-cAMP further and noted 
Epac that bound to this compound had a 3 fold higher vmax than 
Epac bound to cAMP. By testing other cAMP analogues and by 
mutational analysis we found that the 2'-OH atom of cAMP is 
responsible for the super- activation. We propose a model of how it 
communicates with the LID region. 
Experimental Procedure 
Preparation of proteins 
All Epac constructs were expressed as GST-fusion proteins from 
the pGEX-4T2 vector in the E.coli strain CK600K as described 
previously (12). All constructs are human Epac1 and correspond to 
the following amino acids: Epac 149-881, Epac149-328 149-328. 
Mutations were introduced according to the Quickchange Procedure 
(Stratagene). The C-terminal truncated version of Rap1B was 
expressed and loaded with 2’(3’)-O-(N-methylanthraniloyl) 
guanosine diphosphate (mantGDP) as described (13). We refer to 
this construct as Rap1B or simply Rap1 in the text. 
Isothermal Titration Calorimetry 
To analyse the binding of cAMP to the isolated cAMP-binding 
domain a Microcalorimeter (MicroCal Inc.) was used. For details 
see Rehmann et al.2.
In vitro activation of Rap1 
The experiments were performed as described earlier by Rehmann 
et al.2. Briefly, 200 nM of Rap1B loaded with the fluorescent GDP 
analogue mantGDP were incubated in the presence of 20 µM GDP 
(Sigma) and 100 nM Epac. cAMP (Sigma) and analogues thereof 
was added as indicated for the individual experiments. Cyclic 
nucleotides except camp itself were obtained from Biolog Life 
Science Institute (Bremen). The nucleotide exchange was measured 
in real time as a decay in fluorescence using a spectrofluorometer 
“spex1” (Spex Inc.). The origin of the decay is the release of the 
protein bound mGDP, that shows a higher fluorescence intensity in 
the hydrophobic environment of the protein the in the buffer 
solution. The obtained data were fitted to a single exponential decay 
and obtained rate constants (kobs) were plotted against the cAMP 
concentration. The concentration dependency of the rate constants 
were treated as a normal titration experiment.  
All data analysis, fitting and plotting were done with the Grafit 3.0 
program (Erithacus Software). 
Results
Interactions of Epac with various cNMPs  
We have used the isolated cNMP-binding domain of Epac 1, Epac-
RD149-328, to determine the equilibrium dissociation constant Kd for 
the nucleotides cAMP, cGMP, cIMP and cXMP (Fig 1A) by 
isothermal titration calorimetry (ITC). Interestingly, although 
cAMP has the highest affinity (3.3µM) of the cyclic nucleotides 
tested, the affinities of cIMP (6.4µM), cGMP (14 µM) and cXMP 
(20µM) are of similar magnitude. Next we investigated whether 
these nucleotides are able to activate Epac using a fluorescence-
based assay where the ability of Epac to act as a GEF for Rap1 is 
tested with increasing concentration of nucleotide (see experimental 
procedure and (13)). From this we derive the half-maximal 
concentration for activation, AC50, and the maximal rate of 
exchange under saturating concentration of activator kmax. Whereas 
cAMP activated Epac with the expected AC50 of about 45 µM (Fig. 
2A and (8)), neither cGMP (Fig. 2A) nor the other cyclic 
nucleotides (data not shown) were able to activate Epac 
significantly. To investigate whether the failure of cGMP, cIMP 
and cXMP to activate Epac is due to a failure to bind to full-length 
Epac149-881 we measured whether these cNMPs were able to inhibit 
Fig. 1 Schematic representation 
of Epac1 and 2 and the 
structure of cyclic nucleotide 
analogues.  
A. Indicated is the domain
structure of Epac1 with a
Dishevelled, Egl-10, Pleckstrin
(DEP) domain, a cAMP binding
domain (cAMP), a Ras exchange
motif (REM) and a CDC25
homology domain (CDC25-HD).
The deletion constructs used in
this study are indicated. B.
Chemical structures of the cyclic
nucleotides and nucleotide
analogues used in the present
study, with numbering of the ring
positions of the base and the
ribose are indicated in the cAMP
structure. All modifications are
grouped according to the position
of the substitutions. 
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the cAMP induced activation. As shown in Fig. 2B cIMP indeed 
inhibited cAMP induced activation of Epac. The IC50 of cIMP to 
inhibit Epac in the presence of 60µM cAMP is about 200µM, 
compatible with a 2-3 fold lower affinity of cIMP  compared to 
cAMP. Similar results were obtained for cGMP and cXMP (data 
not shown).
The RAAT motif is conserved in the regulatory domains of cAMP 
dependent kinases and it  is replaced by RTAT/N in cGMP 
dependent kinases. It was shown that the A to T mutations in PKA 
change the selectivity from cAMP to cGMP and vice versa (14-16). 
In the case of EpacRD149-328 the A280T mutation does indeed 
increase the affinity for cGMP whereas the affinity for cAMP is not 
altered (Fig. 2C). Nevertheless, in the context of the auto-inhibited 
∆DEP-Epac, the mutant does not show an improved activation 
behaviour after stimulation with cGMP, but rather a 2 fold 
reduction of kmax after activation by cAMP (Fig. 2A). From these 
results we conclude that although a number of cyclic nucleotide can 
bind to Epac, only cAMP is able to activate its GEF activity for 
Rap1. cAMP differs from the other three cNMP's by the structure of 
the nucleotide base, and cGMP, cIMP and cXMP have in common 
that the  6-amino group of the base in cAMP is replaced by oxygen. 
To investigate whether indeed the N6 group is crucial for the 
activation of Epac, we tested the activity of the commonly 
employed N6-phenyl-cAMP analogue in vitro. As expected, this 
compound did not activate Epac (data not shown), but inhibits 
rather efficiently cAMP induced activation in vitro (Fig. 2C). 
Modification of the cyclic phosphate 
The exocyclic oxygens of the phosphate group, which are not 
involved in the ring formation, can be replaced by sulphur in a 
stereo-specific manner generating Rp- and Sp-cAMPS isomers, 
respectively (Fig.1). Rp-cAMPS is an inhibitor of PKA, whereas 
Sp-cAMPS which has a strongly reduced affinity, is able to activate 
PKA (17;18). Similar to the findings for PKA, Rp-cAMPS does not 
active Epac but rather inhibits cAMP-induced activation of Epac 
Fig. 2 cIMP, cGMP and cXMP are inhibitors of Epac.  
A. Rate constants for Epac-mediated GEF reactions were measured under
standard conditions, using 200 nM Rap1•mantGDP in the presence of
100 nM wild-type or mutant Epac with excess GDP, at different
concentration of cyclic nucleotide, from the rate of the decrease in
fluorescence intensity (kobs), as indicated in the Experimental Procedure.
The kobs values were plotted against the indicated cyclic nucleotide
concentration. B. Inhibition of GEF activity was measured under standard
conditions using a constant concentration of 60µM cAMP and the
indicated concentrations of 8-pCPT-cAMP, N6-phenyl-cAMP and cIMP,
respectively. kobs were determined from the single experiments and
plotted against the concentration of cyclic nucleotide. C. The nucleotide
affinity of the single cAMP binding domain (EpacRD149-328) were
determined by ITC as described in Experimental Procedure. 
Fig. 3 Rp-cAMPS acts as an inhibitor of Epac.  
A. The inhibitory properties of Rp-cAMPS were analysed as described in
Fig. 2B. B. The dependency of the exchange activity on the sulphur
substituted analogues Rp-cAMPS and Sp-cAMPS was analysed as
described in Fig. 2A 
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addition, these modifications affect the AC50, many of them 
activating more efficiently than cAMP. Most notable is the 50 fold 
decrease in AC50 of 8-pCPT-cAMP compared to cAMP (Fig. 4). 
Whereas all 8-modifications activate Epac and affect both the kmax
and the AC50, 2-Cl-cAMP has a similar kmax and AC50 for Epac as 
cAMP (data not shown).
Modification of the 2’-position of the ribose 
One of the most striking differences between the cNMP-binding 
domains of Epac and those of other proteins is the presence of a 
glutamine (Q) at position 270 of Epac, which corresponds to a 
glutamate (E) that is totally conserved in all other cAMP- or cGMP-
binding proteins. Since in PKA this glutamate was shown to form a 
hydrogen bound with the 2’-OH group of the ribose (9) and was 
shown to be crucial for high affinity binding (19) we wondered, 
whether Epac would tolerate modifications of the 2’-OH group. Its 
“deletion” in 2’-deoxy-cAMP results in a drastic increase of the 
AC50 and kmax could not be reached even at 1000 µM nucleotide 
(Fig. 5A). This argues that the 2’-OH group is important for binding 
and activation. To maintain the oxygen we generate 2’-O-Me-
cAMP and found a more moderate reduction of the AC50, which h 
was estimated to be in the rage of 100 µM. Surprisingly, 2’-O-Me-
cAMP induced guanine nucleotide exchange rates (kobs) much 
higher then the kmax of cAMP, even though 2’-O-Me-cAMP was 
used at non-saturating conditions.  
Since the 8-pCPT modification was found to decrease the AC50
(Fig. 4A), we wondered whether this positive effect on affinity 
could be combined with the positive effect on kmax of the 2’-O-Me 
substitution. Indeed, 8-pCPT-2’-O-Me-cAMP showed a decreased 
AC50 and an increased kmax (Fig. 5A,C). The AC50 of 8-pCPT-2’-O-
Me-cAMP (1.8 µM) is only slightly lower than the AC50 of 8-
pCPT-cAMP (0.9 µM) and still 25 times lower then the AC50 found 
for cAMP. In addition, the kmax of 8-pCPT-2’-O-Me-cAMP is 7.2 
fold higher than 8-pCPT-cAMP and still 3.6 fold higher than 
cAMP. In order to demonstrate that this superactivation of Epac by 
8-pCPT-2’-O-Me-cAMP is due to a change in equilibrium between 
an active an inactive conformation of Epac, and is not due to any 
different conditions of the assay, we incubated Epac induced by 8-
pCPT-2’-O-Me-cAMP with increasing concentrations of cAMP. 
We find, that with increasing concentrations of cAMP, the GEF 
activity is reduced down to a level observed for cAMP alone. 
Similarly, 8-Cl-cAMP inhibits 8-pCPT-2’-O-Me-cAMP induced 
GEF activity to a level normally achieved by this analogue, which 
is half as much as that of cAMP.  We can thus conclude that the 
diverse effects of the 8-pCPT and the 2’-O-Me modifications on 
inducing GEF activity can be  combined to create a super-activating 
cAMP analogue which specifically activates Epac and can be used 
as a tool to decipher the role of Rap1 in signal transduction 
pathways (11;20).   
Role of the Gln270 in binding and activation 
To analyse the role of Q270 in the interaction with the 2’OH group 
of cAMP side we generated the mutants EpacQ270A and 
EpacQ270E. The mutation Q270E mimics the residue conserved in 
PKA. Importantly, the affinity of cAMP for the isolated cNMP-
binding domains of both mutants was not affected demonstrating 
that unlike in PKA, this residue is not involved in binding of cAMP 
(Fig. 6B). The mutants were then further analysed, in the context of 
Epac149-881,  for their activation properties in response to stimulation 
by cAMP, 2’-deoxy-cAMP and 8-pCPT-2’-O-Me-cAMP (Fig. 6A). 
For cAMP a two fold higher kmax was observed for both mutants, 
whereas the AC50 remains unaffected, indicating that Gln270 is not 
crucial for the activation mechanism of cAMP and has, if anything, 
an inhibitory role on full activation. Activation by 8-pCPT-2’-O-
Me-cAMP is differently affected by the two mutations: whereas the 
Q270E mutation had no effect on the kmax but slightly decreased the 
AC50, the Q270A mutation decreased kmax and left the AC50
unaffected. The AC50 of 2’deoxycAMP is too high to determine 
kmax either for wild-type and mutant proteins (Fig. 6). From these 
results we conclude that the presence of a hydrogen bond donor or 
acceptor in the position of residue Q270 does contribute to normal 
activation by cAMP and super-activation by 8-pCPT-2’-O-Me-
cAMP in a manner that is not immediately obvious in the absence 
of a cAMP-bound 3D structure.
The LID region is involved in super-activation 
Recently we mutated conserved polar residues Glu308, Thr311, 
Arg313 and His317 in the LID of Epac12. As isolated cAMP-
binding domains these mutant proteins have a two fold lower 
affinity for cAMP except H317A for which the affinity for cAMP 
was unaffected. In addition these mutations affected cAMP-induced 
activation of Epac (Rehmann et al.2 and Fig. 7). By comparing the 
effects of cAMP, 8-pCPT-cAMP and 8-pCPT-2’-O-Me-cAMP we 
observe that R313A and T311A have a roughly similar effect on the 
activation of Epac by both cAMP and 8-pCPT-cAMP, but 
surprisingly an opposite effect on the activation by 8-pCPT-2’-O-
Me-cAMP (Fig. 7), R313A did not influence the kmax of 8-pCPT-
cAMP and cAMP but reduced the kmax of 8-pCPT-2’-O-Me-cAMP 
almost two fold. T311A increased the kmax of cAMP and 8-pCPT-
Fig. 6 Q270 plays an important role in the activation mechanism of
Epac.
A. The mutants EpacQ270A and Q270E were generated and compared
with wt with respect to there activation behaviour after stimulation with
cAMP, 2’-deoxy-cAMP and 8-pCPT-2’-O-Me-cAMP. The cAMP and 8-
pCPT-2’-O-Me-cAMP dependency of Epac wt is reproduced from Fig.
5A. B. The table summarises the A50 and kmax values. The kmax are
normalised to the wt protein for the respective analogue (normalisation
within the column). In addition the kmax are normalised to cAMP for the
respective mutant (normalisation within the row), these values are given
in brackets. The affinity of cAMP to EpacRD149-328 as determined by ITC
are given in the first column. 
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Fig. 7 The LID region is directly involved in the activation process.  
A. Four conserved polar residues of the LID region were mutated to Ala and analysed for the dependency of their activity on the cyclic nucleotide 
concentration. The analysis of Epac wt is shown in each individual graph for comparison, values for cAMP-induced activation is taken from Rehmann et al.2.
B. The table shows the AC50 and kmax values. The kmax are normalised to the wt protein for the respective analogue (normalisation within the column). In 
addition the kmax are normalised to cAMP for the respective mutant (normalisation within the row), these values are given in brackets.
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2’-O-Me-cAMP two fold, but has no effect on the kmax of 8-pCPT-
2’OMe-cAMP. For H317A the kmax achieved with 8-pCPT-
2’OMe was greatly reduced compared to wild type, whereas for 
E308A, the kmax was even increased by about 25%. Also, the AC50
of the analogues was affected by the mutations. Most notably, 
although the affinity for cAMP for the isolated cAMP-binding 
domain of T311A and T311A was reduced, the AC50 was 
considerably lower. From these results we conclude that the LID 
region is involved in the super-activation of Epac by 8-pCPT-2’-O-
Me-cAMP. Particularly the differential effect of 8-pCPT-2’-O-Me-
cAMP compared to cAMP and 8-pCPT-cAMP on R313A and 
T311A indicates that the 2’-O-Me-group communicates with the 
LID to induce super-activation.  
Discussion
We have analysed the effect of various cAMP analogues on their 
effects on Epac activation in vitro. We first noted that although 
cGMP, cIMP and cXMP do bind to Epac with an affinity similar to 
cAMP they are unable to activate Epac. This implies that the 
composition of the base, particularly the N6 position, is absolutely 
critical for the activation of Epac. In contrasts, cGMP, cIMP and 
cXMP are competitive inhibitors. Since the IC50 is the upper µM 
range it is unlikely that this inhibition is physiologically relevant. In 
this respect Epac differs from PKA. Both cGMP (14) and cIMP 
(21) are able to fully activate PKA, although only at high 
concentrations. Similarly, N6-phenyl-cAMP inhibits Epac but 
activates PKA (21). All these nucleotides have an identical cyclic-
phosphate ribose group and thus the interaction of the base, 
presumably with the LID determines the difference. Apparently 
alterations the N6 position of cAMP abolishes the ability of cyclic 
nucleotides to activate Epac but not PKA. This implies that suitably 
N6-altered cAMP-analogues may be able to differentiate between 
PKA and Epac.  
With respect to cyclic nucleotide dependent protein kinases, the 
RAAT- and the RTAT/N-motif were identified to determine the 
cAMP and cGMP specificity, respectively. From modelling studies 
an extra hydrogen bound between the 2-NH2-group of the guanine 
and the first threonine in RTAT/N was predicted (22). These 
theoretical considerations were confirmed by side directed 
mutagenesis for both PKA (16;23) and PKG (15), which 
demonstrated an increased cGMP affinity due to the presence of the 
threonine. Similarly, EpacRD149-328A280T showed an increased 
affinity for cGMP as well. However, EpacA280T showed no 
improved activation by cGMP in terms of kmax. Thus the A/T 
conversion increased the affinity of cGMP for Epac, but has no 
effect on the activation of Epac by cGMP. Interestingly, as 
predicted from studies with PKA (14) and PKG (15) the A/T 
conversion did not or only marginally affect the affinity for cAMP. 
However it did reduce the maximal activation of Epac by cAMP, 
showing that the RAAT sequence is not only involved in conferring 
specificity in binding but also in transferring the cAMP binding 
information to the activation of Epac.  
From the structural analysis of Epac and PKA it was clear that the 
cyclic phosphate group is critical for the activation of both proteins. 
Indeed Rp-cAMPS, in which one of the free oxygens of the 
phosphate group is replaced by a sulphur atom, is an inhibitor of 
PKA (17;18), whereas Rp-cGMPS inhibits PKG (24). Indeed, Rp-
cAMPS also inhibits cAMP-induced Epac activation. This supports 
strongly the common activation mechanism of these proteins as 
proposed previously by us (8), i.e. the replacement of the equatorial 
oxygen perturbs the hydrogen bonding between the phosphate and 
an alanine in the PBC and prevents the reorientation of the PBC, the 
first step in the activation of both proteins.  
Modifications at the 8-position of the base are commonly used as 
cNMP-analogues for PKA and PKG, since these modifications both 
increase the permeability for cells and reduce the AC50 to activate 
these proteins (21;25). In particular 8-pCPT-cAMP and 8-Br-cAMP 
are widely use for in vivo experiments. The 8-Br-substitution was 
shown to stabilise the syn conformation of cAMP, the conformation 
of cAMP adopted in the crystal structures of PKAI and PKAII 
(9;10), which provides a possible explanation for the decreased 
AC50. The analogues also have a lower AC50 for Epac compared to 
cAMP, particularly the 8-pCPT-modifictaion resulted in a 50 fold 
reduction in AC50. However, the maximal activation of Epac by 
these analogues is two fold lower compared to cAMP indicating 
that modifications at the 8 position also affect the kmax of the 
protein. However, not all modifications of the 8 positions affect the 
behaviour of cAMP on Epac. e.g 8-ABA-cAMP.  
The highly conserved glutamate in the FGELAL sequence of the 
PBC of PKA, PKG, cyclic nucleotide-gated ion channels and even 
the bacterial CAP protein, is replaced by a glutamine (Q270) in 
Epac1 and a lysine in Epac2. Glutamic acid was found to form a 
hydrogen bond with the 2’-OH group of the cyclic nucleotide and 
was shown to be absolutely essential for the binding of cAMP to 
PKA (19). While the Epac structure analysis (8) showed that the 
corresponding residue would be close to the 2’-OH-group, a 
potential interaction between Q270 would not significantly 
contribute to the binding affinity for cAMP. Neither the AC50 of 
EpacQ270A or EpacQ280E nor the Kd of Epac149-328Q270A or 
Epac149-328Q270E is altered. This suggested that the glutamine in 
Epac is not involved in the direct binding of cAMP and would 
question the necessity of the 2’-OH-group for activation of Epac.  
However, drastic effects on activation of GEF activity with respect 
to both AC50 and kmax were obtained by modifications of the 2’-OH 
group of the ribose. Replacement of the 2’-OH group by H or by 
OCH3 leads to an increase of the AC50, indicating that interactions 
of the 2’-OH-group contribute to the binding of Epac, but not via 
Q270. Indeed, the affinity of 2’-deoxy-cAMP for the cAMP binding 
domain was dramatically reduced. However, this reduction was 
much less, but still ten fold, when the oxygen was preserved by 
replacing the OH-group for an O-Me-group (Christensen, submitted 
for publication). This indicated that the OH group still confers 
binding energy for cAMP to Epac, presumably through its 
interaction the conserved glycine in the FGELAL sequence. 
Interestingly, 2’-O-Me- cAMP (and perhaps 2’-deoxy-cAMP) at 
non-saturated concentration induces kobs-values that are higher then 
the kmax of cAMP mediated activation. Apparently, the 2’-O-Me-
group, shifts the conformational equilibrium of the nucleotide 
bound Epac more efficient to the active site. Combined with the 
increased affinity of the 8-pCPT-group, both modifications resulted 
in a highly specific “superactivator” of Epac (11). The effect of the 
increased kmax is in part mediated by Q270. The kmax of 8-pCPT-2’-
O-Me-cAMP mediated activation of EpacQ270A (but not 
EpacQ270E) is decreased significantly. On the other hand, the kmax
of cAMP mediated activation for both mutants is increased in 
comparison to wild type. This indicates that Q270 disfavours the 
cAMP bound active state but favours the 8-pCPT-2-O-Me-cAMP 
bound active state.
Mutagenesis of the LID demonstrate a role of this region in the 
super-activation behaviour of 8-pCPT-2’-O-Me-cAMP, although 
the role of individual residues in this process is still unclear. A 
potential link between the LID and the OH/OCH3-group and/or 
Q270 is H317. In all known PKA structures a hydrogen bond 
between the glutamate in the FGELAL sequence (corresponding to 
Q270 in Epac1) and a tyrosine/tryptophane in the LID is found. 
This tyrosine/tryptophane may corresponding to H317. Indeed, 
cAMP- as well as 8-pPCT-2’-O-Me-cAMP-mediated activation is 
drastically reduced in EpacH317A. R313 may be specifically 
responsive to the 2’-O-Me-group, since the kmax of cAMP is not 
altered, whereas the kmax of 8-pCPT-2’-O-Me-cAMP is reduced two 
fold. In contrast, T311 may be specifically responsive to the 2’-OH-
group. Further structural and mutational analysis of both the LID 
and the catalytic domain are required to fully understand the 
molecular mechanism of Epac activation by cAMP and cAMP 
analogues.  
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Summarising discussion 
Different proteins are targeted by the second messenger 
cAMP, namely Epac, PKA and cyclic nucleotide 
regulated ion channels in eukaryotes, and the catabolite 
gene activator protein (CAP) in prokaryotes. To all 
these proteins, a cAMP binding domain of the same 
architecture is in common. This implies a common 
general regulation mechanism on the molecular level. 
This also implies an interference of the signalling 
events caused by these proteins as soon as they occur in 
the same cell. In this thesis, the regulation mechanism 
of Epac was investigated and it may now be possible to 
postulate a basic regulation mechanism of general 
validity for proteins regulated by cAMP- and cGMP-
binding domains. 
Regulation of Epac 
Based on the comparison of the crystal structure of the 
cAMP free regulatory region of Epac (chapter 4), with 
the cAMP bound structures of PKA (1;2) and CAP (3), 
we suggest a model of cAMP regulation that is 
summarised in Fig. 1. The major difference between 
the cAMP free structure of Epac (dark grey) and the 
cAMP bound structure of PKA (light grey) is the 
arrangement of the C-terminal part of the cAMP-
binding domain. This helical area shields cAMP 
against the solvent in cAMP bound structures, but is 
found in an open conformation in case of Epac, 
allowing free access for cAMP to the cAMP-binding 
site (part a of Fig. 1). According to the model, binding 
of cAMP rearranges this part of the protein by 
movement of a helix, called the hinge, closer to the 
core of the domain. How does cAMP cause this 
movement? Part b of figure 1 shows a magnification of 
the hinge region. It is not possible for the hinge of the 
cAMP free structure to adopt the same angle as in the 
cAMP bound structure, since a phenylalanine of the 
helix would clash with a leucine from a loop of the core 
domain, which is rearranged upon cAMP binding. This 
loop is tighter in PKA and thereby eaves space for the 
phenylalanine. The loop, called phosphate binding 
cassette (PBC) (4), is highly conserved in sequence in 
all cAMP binding domains and forms hydrogen bonds 
to the phosphate sugar moiety of the cyclic nucleotide
Fig. 1 Regulation of Epac by cAMP.
A superimposition of the second 
cAMP-binding domain of Epac (dark 
grey) and PKA (light grey) is show in 
part a. Parts of PKA which are 
identical to Epac are omitted for 
clarity. The N- and C-terminus are 
indicated. Part b shows a 
magnification of the hinge region 
containing the conserved 
phenylalanine and leucine, which 
blocks the movement of the C-
terminal helix closer to the core in the 
absence of cAMP. Part c shows a 
magnification of the Phosphate 
binding cassette (PBC). In the 
absences of cAMP parts of the PBC 
are in the correct position to accept 
hydrogen bonds from cAMP, whereas 
other parts have to undergo 
conformational rearrangements for 
cAMP binding. The parts of this 
figure and of all other figures 
containing plots of protein structures 
were generated using MolScript (30) 
and Raster3D (31). 
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(1;2). A magnification of the PBC is shown in part c of 
figure 1. Also in the absence of cAMP, some parts of 
the PBC are in the correct conformation to accept 
hydrogen bonds, others are not. These parts will move 
closer to cAMP to form the hydrogen bonds. The PBC 
is tightened by this rearrangement and the leucine is 
moved away to allow the helix to flip over. This 
mechanism was confirmed by mutagenesis studies 
(chapter 4).
It is possible to inhibit the isolated catalytic region by 
addition of the isolated regulatory region of Epac1 in 
trans. The inhibition could be released by the addition 
of cAMP (5). This experiment demonstrates a direct 
protein-protein interaction between the regulatory and 
the catalytic region of Epac, which is released upon 
cAMP binding. These studies were extended to Epac2 
(chapter 2), where it was found that the second cAMP 
binding domain of Epac2 is sufficient to inhibit the 
catalytic domain in trans. Furthermore, we 
demonstrated the involvement of the VLVLE motif of 
Epac, a sequence that directly follows the C-terminal 
helix of the cAMP-binding domain, in the interaction 
with the catalytic region of Epac (chapter 3). The 
activation properties of Epac are very sensitive to 
mutations in the whole area of the C-terminal helix and 
the VLVLE-motif (chapter 3 and 5). Thus the C-
terminal helix and the VLVLE stretch of the cAMP-
binding domain is a pivotal element of the 
intramolecular binding interface of Epac. 
Is it possible to extend this basic model of regulation to 
other cAMP binding proteins? The following section 
will focus on CAP and PKA, the only other cAMP-
binding proteins for which structural information is 
available.
Regulation of CAP 
The cAMP-binding domain of CAP (catabolite gene 
activator protein) was the first one for which structural 
data was available, and thus it was used as a model for 
PKA and cyclic nucleotide gated ion channels. 
Different states of CAP were crystallised: the 
homodimer of CAP bound to cAMP (3) and the 
homodimer of CAP bound to cAMP in complex with 
DNA (6) (Fig. 2A). However, no structural information 
of the cAMP free state is available so far. The crystal 
structure of CooA was determined recently (7). CooA 
is a transcription factor of the CAP family and consists 
of a DNA-binding domain, which is structurally 
equivalent to the DNA-binding domain of CAP, and a 
heme containing domain, which is structurally 
equivalent to the cAMP-binding domain of CAP. The 
heme group is localised at the position corresponding 
to cAMP in the CAP structure. Since CooA is activated 
by the binding of carbon monoxide (CO) to heme and 
since the structure was determined in the absence of 
CO, this structure could be understood as a model for 
the inactive, ligand free state of CAP.
The major difference between these three structures is 
the relative orientation of the DNA-binding domain 
and the ligand-binding domain. The domains itself 
differs only marginally from each other. The 
orientation of the DNA-binding domain is incompatible 
with DNA binding in the CooA structure, since it does 
not allow a concomitant binding of both domains 
(compare Fig. 2B with Fig. 2D). The comparison with 
CAP suggest that ligand binding to transcription factors 
of the CAP family induces a flipping of the DNA 
binding domain by 180° relative to the cAMP-binding 
domain (compare Fig. 2B with Fig. 2C). The DNA-
binding domain of chain A is in the correct orientation 
after ligand binding, whereas an additional induced fit 
upon DNA-binding is required in chain B (compare 
Fig. 2C with Fig. 2D).  
Although the comparison of CooA and CAP gives deep 
insights into the behaviour of the DNA-binding 
domains, its use to draw conclusions for the ligand-
binding domains is limited. Crucial residues involved 
in cAMP binding are not conserved between CAP and 
CooA. A movement of the cAMP binding domain 
relative to the C-terminal helix was suggested from the 
first cAMP bound structure of CAP. cAMP is buried 
deeply in the cAMP-binding pocket so that an exit and 
entry way for this cyclic nucleotide has to be generated 
(Fig. 2F). A solution of this problem is not evident 
from the CooA structure. Although the C-terminal 
helices are rotated relative to each other in comparison 
to CAP, there is still no easy access to the ligand 
binding site. This is easy to understand since the 
binding site of CooA has to be accessible only for the 
small CO. In conclusion, it is not clear how cAMP 
binding to the cAMP-binding domain is transferred to 
the rearrangement of the DNA-binding domains. Still, 
a movement of the cAMP-binding domains relative to 
the C-terminal helices would give cAMP access to the 
binding site, and this movement (as a movement of the 
C-terminal helix) is predicted from the model based on 
our analysis of Epac. 
A role of the base binding region in regulation? 
The base binding region (BBR) is situated in a loop 
between two β-sheets in the core structure of the 
cAMP-binding domain. Based on studies with CAP it 
was suggested to be involved in communication of 
cAMP binding to remote parts of the protein. In some 
crystal forms of CAP, hydrogen bonds between the 
DNA-binding domain and the BBR were observed 
(3;6). However, the BBR is very divergent and neither 
conserved between different types of cAMP-binding 
domains nor between cAMP-binding domains of the 
same family. The BBR often contains insertions, which 
differ in length by up to 12 residues. In fact, this loop is 
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Fig. 3 A role of the base binding region in regulation. The 
cAMP binding domains of Epac (chapter 4), PKA (1;2) and 
CAP (3) were structurally superimpose. In the figure only 
the BBR is shown (the complete superposition is shown in 
chapter 4 Fig. 3A). As can be seen, the BBR of the 
individual proteins differs in conformation and length. With 
the data available it is not possible to correlate a specific 
conformation with the nucleotide states. 
the most divergent part of the core of all cAMP-
binding domains solved so far (Fig. 3). The structural 
flexibility of the BBR is reflected by (a) high B-factors; 
the loop is not visible in the electron density in some 
structures and by (b) different conformations of the 
BBR in the single domains of the CAP dimer. 
Independently of whether these considerations make a 
role of the BBR in regulation likely or not, it is not 
possible to draw any conclusion from a comparison of 
the cAMP free structure (Epac) with the cAMP bound 
structures (PKA and CAP). This is due to the fact, that 
it is not clear whether a different conformation has to 
be attributed to cAMP binding or to the different 
sequence of the BBR. In addition, we found no 
evidence for a role of the BBR for regulation of Epac 
activity during our biochemical analysis. 
Regulation of PKA
The inactive complex of PKA consists of two 
regulatory subunits (R) and two catalytic subunits (C). 
cAMP binding to this complex results in the 
dissociation of the catalytic subunits from the complex. 
The free catalytic subunits are catalytically active 
kinases. Whereas structural information of the cAMP 
bound regulatory subunit(1;2) as well as of the catalytic 
subunit in complex with AppNHp and an inhibitory 
peptide (8;9) is available, no crystal structure for the 
inactive R2C2-complex was obtained so far. 
A low resolution model for the R2C2-complex was 
derived from neutron and x-ray scattering experiments 
(10). This model is shown in a cartoon like fashion in 
Fig 4A. The regulatory domains interact with each 
other through an N-terminal dimerisation domain in an 
antiparallel orientation. This orientation is confirmed 
by NMR-studies of the dimerisation domain (11). The 
linker region, which contains the pseudosubstrate 
sequence, connects the dimerisation domain to the 
cAMP-binding domains. The catalytic subunits are 
bound to the pseudosubstrate sequences as well as to 
the cAMP-binding domains. An interaction of both 
catalytic subunits with each other is excluded by 
neutron scattering data (10). Thus the interaction 
between each R and the individual C is independent of 
the respective other R-C pair. This is confirmed by a 
deletion mutant of R, lacking the dimerisation domain 
still being able to bind and to inhibit the catalytic 
subunit by the formation of an RC-complex (Fig 4A) 
(12;13).
The binding interface of the R-subunit was narrowed 
down further by biochemical experiments. Despite 
deletion of the N-terminal dimerisation domain, 
deletion of the C-terminal cAMP-binding domain does 
not interfere with the inhibitory properties of the R-
subunit (Fig. 4A) (12;14;15). The minimal requirement 
for proper binding and inhibition therefore is the 
pseudosubstrate sequence and the first cAMP binding 
domain. This indicates a less important role of the 
second cAMP binding domain. Since cAMP binding to 
the regulatory subunit is a cooperative process, it was 
suggested that cAMP first binds to the second cAMP 
Fig. 2 Regulation of CAP by cAMP. A. The complete crystal structure of the CAP dimer in complex with cAMP and
DNA is shown in the left panel. The right panel shows a separation of the DNA-binding and the ligand-binding domains
for clarity of presentation. The C-terminal helix of the cAMP-binding domain, which connects the cAMP-binding domain
to the DNA-binding domain is shown in both parts. To reconstruct the complete structure the DNA-binding domain has to
be rotated by 90° and moved downwards. The C-terminal helices, shown for both parts, would be superimposed after the
transformation. CAMP-BD, cAMP-binding domain; DNA-BD, DNA-binding domain. B, C, D. The separated DNA-
binding domains (upper panel) the separated cAMP-binding domains (middle panel) and a schematic representation
(lower panel) are shown for the ligand free structure of CooA (B) the ligand bound structure of CAP (C) and the ligand
bound structure of CAP in complex with DNA (D). All domains are shown in the same orientation as obtained from a
superimposition of the ligand binding domains of chain A. 
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binding domain and thereby primes cAMP binding to 
the first domain. However it is not shown, that binding 
necessarily has to occur sequentially. 
The inhibition itself is mediated by the pseudosubstrate 
sequence, which binds to the active site instead of the 
substrate protein. PKA can be inhibited by peptides 
derived from the pseudo substrate sequence of PKA 
and PKI (16;17). However the affinity of the pseudo 
substrate sequence of R is only in the micro molar 
range (18), whereas a construct containing the 
pseudosubstrate sequence and the first cAMP-binding 
domain can bind the C-subunit with 10 nM affinity 
(14). Mutations in the pseudo substrate sequence lead 
to an R-subunit that can bind but not inhibit the C-
subunit and thus forms an RC-complex with full kinase 
activity in the absence of cAMP (19). It is thus the first 
cAMP binding domain that binds to the catalytic 
subunit and thereby positions the pseudo substrate 
sequence in optimal vicinity to the active site. 
The binding site in the first cAMP-binding domain was 
Fig. 4 Regulation of PKA by cAMP. A. Cartoon-like model of the quaternary structure of PKA. The model summarises
data from neutron scattering experiments and from biochemical analysis. Each catalytic subunit (C-subunit) is bound
independently to a regulatory chain. cAMP binding causes the dissociation of the R2C2-complex to R2(cAMP)4 and 2C.
The released C-subunits became catalytically active. The right panel shows the minimal complex of a t truncated
regulator chain that can still be regulated by cAMP. ψ pseudo substrate sequence. B,C. The first cAMP-binding domain
of RI (B) and RII (C) are shown. The localisation of the N-terminal pseudo substrate sequence ψ, that is not visible in the
electron density, is indicated. The second, C-terminal cAMP-binding domain is omitted for clarity. Region identified by
H/2H-exchange experiments as a potential binding interface for the catalytic subunit are coloured in black. The interface
consist mainly of an helix N-terminal and C-terminal of to the core of the first cAMP-binding domain. A rearrangement
of the C-terminal helix upon cAMP-binding would alter this interface. 
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mapped by 1H/2H exchange experiments (20;21). In 
this way, areas in the R-subunit were identified that are 
protected against 2H-incorporation in the presence of 
the catalytic subunit. In addition to the pseudosubstrate 
sequence, a helix N-terminal to the core of the first 
cAMP-binding domain as well as the C-terminal helix 
of the first cAMP-binding domain were protected in RI 
(20) and in RII (21) (Fig. 4B,C). The importance of 
these region for the interaction with the catalytic 
subunit is in agreement with mutational studies (22). 
Thus the C-terminal helix as well as an N-terminal 
helix of the first cAMP-binding domain is pivotal parts 
of the binding interface for the catalytic subunit. A 
movement of the C-terminal helix, as predicted from 
our analysis of Epac, would change the relative 
positions of the N- and the C-terminal helix. It is 
tempting to speculate that this movement would 
destroy the binding interface formed by these helices. 
A common feature in the regulation mechanism of 
Epac and PKA is the mode of inhibition. In both cases 
it is mediated by a protein-protein interaction between 
the cAMP-binding domain and the catalytic region, 
which is released upon cAMP binding. Many evidences 
for this intramolecular interaction of Epac were 
presented in this thesis. Most likely it is possible to 
extend this mechanism to PKG. X-ray scattering 
experiments suggested a large size increase of PKG 
upon cGMP binding in one dimension (23). This is in 
agreement with the release of an intramolecular 
interaction between the cGMP-binding domains and 
the kinase domain. 
For all three types of cAMP regulated proteins of 
which structural information is available an important 
role of the C-terminal helix is evident and also the 
regulatory properties of cyclic nucleotide gated ion 
channels are influenced by alterations in this helix (24). 
The cAMP-binding domain is used in all of these 
proteins as a switch module, which works with the 
same basic principle. cAMP-binding is converted into a 
movement of the C-terminal helix by a relatively small 
rearrangement of the PBC. The C-terminal helix differs 
in these proteins and allows therefore the connection of 
cAMP binding to such different functions as nucleotide 
exchange activity or kinase activity. 
Specific targeting of Epac 
The common cAMP-binding domain in different 
receptor proteins leads to an interference of the 
signalling pathways controlled by these proteins. This 
complicates the analysis of cAMP mediated effects in 
in vivo systems. The basis for the development of Epac 
specific cAMP analogues is the identification of Epac 
specific feature of cAMP binding. A combination of a 
mutational analysis of Epac1 and the analysis of a wide 
variety of cAMP analogues was undertaken (chapter 5). 
An individual feature of Epac is the absence of 
glutamic acid in the highly conserved consensus 
sequence FGELAL found in other cAMP-binding 
proteins. In fact, the glutamic acid was expected to be 
totally conserved in all cAMP-binding domains and to 
be absolutely required for binding of cAMP to PKA 
(25). However, mutations of the corresponding 
glutamine in Epac to either glutamic acid or alanine do 
not influence the binding affinity for cAMP. The Epac 
specific activator 8-pCPT-2’-O-Me-cAMP makes use 
of this unique feature of Epac. The glutamic acid is 
known to form hydrogen bonds to the 2’-OH group of 
cAMP in PKA (1;2), and thus PKA does not accept 
modifications of the 2’-position. This is different in 
Fig. 5 Specific activation of Epac. 8-pCPT-2’-O-Me-cAMP was identified as an analogue that activates specifically
Epac. It can be combined with experiments using unspecific cAMP stimuli or the PKA specific inhibitor H89. Thus it is
possible to distinguish PAK and Epac mediated effects from each other. 
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Epac: The 2’-O-Me-group even increases the activation 
potency as compared to cAMP, although this is 
associated with a reduction of affinity. However, the 
reduction of affinity can be overcome by the addition 
of the 8-pCPT modification, and thus 8-pCPT-2’-O-
Me-cAMP has higher activation potency and higher 
affinity for Epac1 than normal cAMP. These features 
combined with high membrane permeability due to the 
hydrophobic  8-pCPT modification make this analogue 
useable for in vivo experiments (26;27). 
This now allows to distinguish between PKA and Epac 
mediated effects (Fig. 5). 8-pCPT-2’-O-Me-cAMP can 
be used to activate Epac specifically. A combined 
activation of Epac and PKA is possible by the 
application of cell permeable cAMP-analogues such as 
8-Br-cAMP or 8-pCPT-cAMP. A specific inhibition of 
PKA is possible by the use of H89, an inhibitor that 
targets the catalytic subunit of PKA (28;29) and 
therefore does not interfere with Epac. 
The studies presented in this thesis contribute to our 
understanding of how cAMP regulates proteins 
containing cAMP-binding domains. The model of a 
general mechanism for this regulation process was 
presented. The example of 8-pCPT-2’-O-Me-cAMP, a 
specific activator of Epac, demonstrate that it should be 
possible to develop Epac specific inhibitors and PKA 
specific activators as well. 
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Summary
The role of cAMP as a second messenger in cellular signalling is well established. In the eukaryotic cell the 
targets of cAMP are PKA, cyclic nucleotide gated ion channels and Epac. All these proteins have a cAMP-
binding domain of same architecture in common. Its function is to bind cAMP and thereby sense the presence of 
cAMP. Binding of cAMP to this sensor domain is transformed into an altered property of the whole protein. In 
spite of the important role of cAMP in regulating cellular events, the knowledge on a molecular level of how 
cAMP binding is translated into protein action was limited so far. For a long time structural information was 
available only for cAMP-bound (i.e. “active”) cAMP-binding domains, but information of cAMP free (i.e. 
“inactive”) cAMP-binding domains was missing. 
We determined the cAMP free crystal structure of the regulatory region of Epac2 containing two cAMP-binding 
domains. The high conservation of both sequence and structure between Epac and PKA allows to compare these 
structures as representatives of the ligand bound and the ligand free state of cAMP-binding domains in general. 
From these analyses a general model was developed of how cAMP-binding is sensed by cAMP-binding domains. 
A relative small rearrangement of residues directly involved in cAMP binding is transduced to a reorientation of 
the C-terminal helical part of the cAMP-binding domain. The helices of the different classes of cAMP-regulated 
proteins have common features related to the rearrangements induced by cAMP and unique features to allow 
communication to the respective remote parts of the protein. By adaptation of the C-terminal helix to the 
individual requirements in the context of the regulated protein class, the cAMP-binding domain can be used as an 
universal switch unit. 
The critical importance of this helix for the regulation of PKA, CAP and cyclic nucleotide gated ion channels is 
described in the literature and was shown for Epac by various approaches in this thesis. In Epac the helix forms an 
interface interacting with the catalytic region. This interaction blocks the catalytic centre in the absence of cAMP. 
This binding and therefore the blockage is terminated after binding of cAMP. 
To complete the structural investigation, extensive biochemical analysis was undertaken. This confirmed already 
mentioned the importance of the C-terminal helix and corroborated the mechanism suggested for cAMP sensing. 
In addition, the requirements for productive cAMP-binding and activation were characterised. Thus, the action of 
Epac specific activators such as 8-pCPT-2’-O-Me-cAMP can be explained. This analogue is able to activate Epac 
with higher efficiency than normal cAMP, but can neither activate nor inhibit PKA. These studies showed also 
that it is in principle possible to inhibit Epac with certain cAMP analogues. Based on these findings it should be 
possible to develop Epac specific inhibitors. This will allow the specific investigation of Epac mediated effects. 
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Samenvatting in het Nederlands 
cAMP heeft een welbekende rol als een ‘boodschappermolecuul’ in signaal transductie. In de eukaryotische cel 
zijn de doeleiwitten van cAMP PKA, cyclic nucleotide gated ion channels, en Epac. Al deze eiwitten hebben 
dezelfde structuur van hun cAMP bindend domein met elkaar gemeen. De functie van dit domein is het binden en 
daardoor waarnemen van cAMP. Binden van cAMP aan dit domein leidt tot een verandering van de 
eigenschappen van het gehele eiwit. Hoewel cAMP een belangrijke rol speelt in regulatie van cellulaire processen, 
is de kennis van hoe precies binding van cAMP wordt vertaald in verandering van de eigenschappen van het 
gehele eiwit op moleculair niveau beperkt. Gedurende lange tijd was alleen structurele informatie beschikbaar van 
cAMP-gebonden (‘actieve’) cAMP bindingsdomeinen, maar informatie over cAMP-vrije (‘inactieve’) cAMP 
bindende domeinen ontbrak. 
Wij hebben de cAMP-vrije kristalstruktuur bepaald van het regulatiedomein van Epac2, welke twee cAMP 
bindende domeinen bevat. Omdat zowel de sequentie als de struktuur van de regulerende domeinen van Epac en 
PKA goed geconserveerd zijn, is het mogelijk de structuur van de ligand-gebonden en ligand-vrije cAMP 
bindende domeinen met elkaar te vergelijken. Zodoende stellen we een algemeen model voor waarmee verklaard 
kan worden hoe binding van cAMP waargenomen wordt door cAMP-bindende domeinen. Een relatief kleine 
plaatsverandering van aminozuren die direct betrokken zijn bij binding van cAMP leidt tot een plaatsverandering 
van de C-terminale helix van het cAMP bindende domein. De helixen van de verschillende soorten cAMP-
gereguleerde eiwitten bezitten algemene eigenschappen die gerelateerd zijn aan de plaatsveranderingen die in 
gang gezet worden door cAMP, en unieke eigenschappen die communicatie met verderop in het eiwit gelegen 
domeinen toestaan. Door aanpassing van de C-terminale helix aan de individuele voorwaarden in de context van 
de gereguleerde eiwitklasse, kan het cAMP bindende domein gebruikt worden als een universele schakelaar. 
Het belang van deze helix voor de regulatie van PKA, CAP, en cyclic nucleotide gated ion channels is beschreven 
in de literatuur, en is in dit proefschrift op verscheidene manieren ook aangetoond voor Epac. In Epac vormt de 
helix een ‘interface’ die een interactie aangaat met het katalytische domein. In afwezigheid van cAMP blokkeert 
beze interactie het katalytische centrum. Deze binding, en daarmee de blokkade, wordt opgeheven door binding 
van cAMP. 
Om de studie van de structuur af te maken, is een intensieve biologische analyse gedaan. Dit bevestigde het boven 
genoemde belang van de C-terminale helix en sterkte het gesuggereerde model voor het waarnemen cAMP. 
Daarnaast werden de voorwaarden voor productieve cAMP binding en activatie gekarakteriseerd. Zodoende kan 
nu het effect van Epac-specifieke activatoren, zoals 8-pCPT-2’-O-Me-cAMP, worden verlaard. Deze analoog kan 
Epac activeren met hogere efficientie dan gewoon cAMP, maar kan PKA noch activeren, noch remmen. 
Bovendien toonden deze studies aan dat het in principe mogelijk is om Epac te remmen met bepaalde cAMP 
analogen. Gebaseerd op deze bevindingen zou het mogelijk moeten zijn om Epac-specifieke remmers te maken, 
waarmee beter onderzoek naar de effecten van Epac gedaan kan worden.
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dem Drucken Deiner Doktorarbeit etwas früher an. Rado and Dennis good luck with some more structures. PD 
Dr. M. Reza Ahmadian, Du musst alle Deine Jungs zusammenhalten und sehen das der Laden läuft. Ah, Silke, Du 
machst das auch schon so. Patricia, vier Jahre war ich so zu sagen Gast bei Euch im Labor und Du hast eine 
Menge meiner Unordnung ertragen, wie auch immer, es hat mir gut gefallen. Delia, success with your projects. 
All die schönen Müller Mädels, Slava, Nadine, Anette, Sonja, Christina, Eva, Mareike, ach ja und Maria, so ist die 
Forschung. Alice, Du bist zwar bei Peter, aber gehörst doch auch hier genannt. Beate, singe weiter und allzeit 
freie Strecke zwischen Dortmund und Oberhausen. Taisa, you are working now on the bench, on which I started 
my PhD thesis four years ago. I hope you will enjoy it as much as I did. Jorrit, it is fun to combine our in vivos 
and in vitros and to go trough the different levels of pain of writing a thesis. A good start for your emigreren. 
Revathy, you appear the first time in Dortmund when I came back the first time from Utrecht, I will never forget 
the first experiment you, Gerrit and me did together: light scattering at the fluorometer, we had to change to 
second order for detection. Doro, Du bist die Geheimwaffe Freds, keine Klonierung zu schwer, keine Klonierung 
zu eilig und natürlich auch sonst universell einsetzbar. Lydia, you are the mother  of the Bos-Lab. Gerrit, ich 
glaube ich habe Deinen Rekord, Doktorand mit der längsten Vergangenheit am Institute, geschlagen. Marita, you 
survived the cold and rainy Netherlands, enjoy the sunny Spain. I am sorry, that I never obtained positive in vitros 
for you. Marta B. maybe we should do a nice in vitro with your KIAA. Robert (der mit einem b), wir sollten hin 
und wieder mal was durchregulieren, Essen, Akroplois und solche Sachen. Dank für Deine Mühe mit meiner 
Thesis. Juliane, weiterhin viel Spaß mit Sequenzanalyse und Familienforschung, Du wirst schon noch beweisen, 
dass Ras die Urmutter aller GTPase ist. Martina, Mrs. BTS, die BTS hat mit Dir gelebt. Kim, it was fun to 
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Du gehörst zum Urgestein des Institutes, nichts gegen Deine Arbeit, aber ich hoffe Du bekommst niemals meine 
Lunge zu sehen. Geert, whenever I gave a talk in Utrecht, you had Chocoladehagel van der Ruijter for Lunch. 
How are you handling this in the States? Uli, Du warst die Zellkultur in Dortmund, deine Promotion haben Dich 
zwar viele Möhren gekostet, aber ich hoffe es wird sich für Dich lohnen. Alma, ich denke, Du hast eine 
Weltrekord in der Herstellung und Aufreinigung von Epac Mutanten aufgestellt. Mein Proteinnachschub war 
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Utrecht. Utz, gibt es eine Methode mit der Du nicht Dimerisierung untersucht hast? Margarita, you are bringing 
the second dimension to our lab. Christina, Königin der Stopped Flow und der Doppelmutantenzyklen. Rita, oder 
wie Fred es ausdrückt, Rita kann das, Rita weiß das, frag mal Rita, Rita macht das. Ingrid, you did always a good 
job as comity member for Labstapdag and other Lab events, which I always enjoined as big fun. Rolf, 1000 
Höhenmeter plus Schneesturm, wir waren in der selben Leistungsklasse und immer gut mit Schirm ausgerüstet. 
Boriana, der Schritt Deiner Schuhe macht Dich unverkennbar, man hört am Wochenende gleich ob Du im 
Institute bist oder nicht. Daniel, noch ein alter Bochumer, den es nach Dortmund verschlagen hatte. Zhao, you 
was a room mate in my first office. I really liked this office. Savi, have a good start in the world of companies, but 
never forget how much fun research could be. Alex, alter Wolf, wir haben so mache S-Bahn Fahrt miteinander 
verbracht. Wie war das Toxikologe in Singapur oder Australien? Australien hat den Vorteil, das jedes Viech das 
da rumkrabbelt das giftigste seiner Art weltweit ist. Kris, nobody reaches your speed in presenting her or his 
results during work discussion. Alex B., ich habe nie jemanden getroffen, der mit größerer Zielstrebigkeit, 
Hartnäckigkeit und Ausdauer ein Protein aufzureinigen gesucht hat. Ingrid V., man könnte wirklich meinen die 
Computer würden auf die hören, keine Gelegenheit, für die Du kein kleines Script schreiben kannst. Henriette, 
unsere Pflanzenfrau, ich hoffe Arabidopsis treibt noch ein paar schöne Blühten für Dich und Deine Arbeit. Marta, 
I think Rheb is a lot of fun, lets find some effectors and some GEFs. Melanie, Du hast Deine Zellen mit vielen, 
vielen Ras-Injektionen sehr gequält, möge die Wissenschaft Dir verzeihen. Joost, I am looking forward for nice 
co-operation, you are the person in the lab the students trust in. Atsushi, oskare sama dischta (die Schreibweise ist 
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really enjoy to work with you, I learned a lot from you, and driving the car at ESRF was fun. Leo, when ever you 
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